期刊文献+

LY294002对人肾透明细胞腺癌细胞增殖和凋亡的影响 被引量:3

Effect of LY294002 on Cell Proliferation and Apoptosis in Human Renal Clear Cell Adenocarcinoma
下载PDF
导出
摘要 目的探讨PI3K-Akt信号通路PI3K抑制剂LY294002对人肾透明细胞腺癌786-0细胞增殖和凋亡的影响。方法采用MTT法检测LY294002对786-0细胞增殖能力的影响,倒置显微镜观察不同浓度及时间点处理LY294002对786-0细胞形态的影响,Hochest染色检测其对786-0细胞凋亡的影响。结果 MTT结果显示LY294002对细胞增殖表现出显著抑制(P<0.05或P<0.01,vs阴性),并表现为药物剂量和时间的依赖性,形态学显示,相对于正常细胞,LY294002可以使细胞生长受到不同程度的抑制,表现为体积缩小,突起变少等现象,Hochest染色结果显示,随着LY294002浓度的加大,细胞逐渐出现染色质凝聚,出现凋亡小体进而完成凋亡。结论 PI3K抑制剂LY294002可明显抑制786-0细胞增殖,促进786-0细胞凋亡,并且呈现浓度依赖性变化。 Objective The effect of PI3K inhibitor LY294002 of PI3K-Akt signal pathway on proliferation and apoptosis of 786-0 cell. Methods Effects of LY294002 on the proliferation ability of 786-0 cells were detected by MTT method. effect of different concentrations and time points of LY294002 treatment on the morphology of 786-0 cells were monitored by inverted microscope. Hochest staining was used to detect the effect on the apoptosis of 786-0 cells. Results LY294002 showed a significant inhibition on the proliferation of cells( P &lt; 0. 05 or P &lt; 0. 01,vs negative) was dependent on dose and time. Morphological observation indicated that LY294002 inhibited the cell growth at different degree,performance for the volume reduction,projection less. The results of Hochest staining displayed that with the increase of LY294002 concentrationthe cells gradually appeared chromatin condensation and apoptotic bodies,and then complete apoptosis. Conclusions PI3K inhibitor LY294002 could inhibit the proliferation of 786-0 cells,cause apoptosis and present concentration-dependent changes.
出处 《宁夏医科大学学报》 2013年第8期877-880,954,共5页 Journal of Ningxia Medical University
关键词 LY294002 肾癌 增殖 凋亡 LY294002 human renal clear cell adenocarcinoma proliferation apoptosis
  • 相关文献

参考文献6

二级参考文献47

  • 1黄玉钿,张声,郑曦,吴钦穗,黄双月,杨发端.乳腺癌中黏着斑激酶、抑癌基因PTEN编码蛋白的表达与生物学行为相关性分析[J].中华实验外科杂志,2005,22(10):1201-1202. 被引量:8
  • 2Zbar B,Klausner R,Linehan WM.Studying cancer families to identify kidney cancer genes.Annu Rev Med,2003,54:217-233. 被引量:1
  • 3Escudier B,Eisen T,Stadler WM,et al.Sorafenib in advanced clearcell renal-cell carcinoma.N Engl J Med,2007,356:125-134. 被引量:1
  • 4Motzer RJ,Hutson TE,Tomczak P,et al.Sunitinib versus interferonalfa in metastatic renal-cell carcinoma.N Engl J Med,2007,356:115-124. 被引量:1
  • 5Hennenlotter J,Ohneseit PA,Simon P,et al.PTEN and p27Kipl are not downregulated in the majority of renal cell carcinomas-implications for Akt activation.Oncol Rep,2008,19:1141-1147. 被引量:1
  • 6Sourbier C,Lindner V,Lang H,et al.The Phosphoinositide 3-Kinase/Akt Pathway;A New Target in Human Renal Cell Carcinoma Therapy.Cancer Res,2006,66:5130-5142. 被引量:1
  • 7Linehan WM,Zbar B.Focus on kidney cancer.Cancer Cell,2004,6:223-228. 被引量:1
  • 8Brazil DP,Yang ZZ,Hemmings BA.Advances in protein kinase B signalling:AKTion on multiple fronts.Trends Biochem Sci,2004,29:233-242. 被引量:1
  • 9Shin Lee J,Seok Kim H,Bok Kim Y,et al.Expression of PTEN in Renal Cell Carcinoma and Its Relation to Tumor Behavior and Growth.Journal of Surgical Oncology,2003,84:166-172. 被引量:1
  • 10Velickovic M,Delahunt B,Mclver B,et al.Intragenic PTEN/MMAC1 loss of heterozygosity in conventional (clear-cell) renal cell carcinoma is associated with poor patient prognosis.Mod Pathol,2002,15:479-485. 被引量:1

共引文献27

同被引文献24

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部